This harmonised draft guideline explains how patient preference studies (PPS) can be designed, conducted, analysed and submitted to support drug development and regulatory evaluation, including benefit–risk assessment and maintenance of approvals. It clarifies that PPS generate structured insights into what matters most to patients when weighing treatment attributes such as outcomes, risks and other relevant characteristics, and provides general methodological considerations intended to improve the quality and usability of patient preference information in regulatory contexts.
